Efficiency Bows To Scrutiny: '90s Drug Development Timelines Have Doubled
Executive Summary
The time it takes to get a new drug candidate through clinical trials and onto the market has almost doubled since the late 1990s – but timescales for discovering new drug candidates haven't changed over the past 15 years.
You may also be interested in...
Half of 2016 Biotech IPOs Positive At Mid-Year; 2015 Success Rate Sours
It hasn't been easy for biopharmaceutical firms to go public in the US during 2016, but as of the end of June the scrutiny seems to be paying off – at least for investors in half of this year's first-half initial public offerings.
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.